Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3017001 | 0.93 | TP53 (0.40) | HTR7GAATP53MAPTALDH1A1 | |
| SCHEMBL3019226 | 0.93 | TP53 (0.39) | HTR7GAATP53MAPTALDH1A1 | |
| SCHEMBL3008114 | 0.92 | CTSS (0.42) | HTR7TP53MAPTALDH1A1RAB9A | |
| SCHEMBL3019701 | 0.92 | DRD2 (0.37) | HTR7GAAMAPTALDH1A1RAB9A | |
| SCHEMBL3015458 | 0.92 | MAPT (0.36) | GAATP53MAPTALDH1A1RAB9A | |
| SCHEMBL3012728 | 0.91 | HTR7 (0.41) | HTR7GAATP53MAPTALDH1A1 | |
| SCHEMBL3007912 | 0.90 | SMN1; SMN2 (0.38) | GAAMAPTALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL3018365 | 0.89 | SMN1; SMN2 (0.36) | HTR7GAATP53MAPTALDH1A1 | |
| SCHEMBL3014222 | 0.89 | MAPT (0.43) | HTR7GAATP53MAPTALDH1A1 | |
| SCHEMBL3006012 | 0.88 | MAPT (0.39) | GAAMAPTRAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | HTR7 1836/4885PTGDR 3023/4885PTGDR2 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.